Filing Flows › Cytek Biosciences (CTKB) › Q1 2025
Cytek Biosciences (CTKB) Q1 2025 earnings results (first quarter 2025)
10-Q filed May 8, 2025
Cytek Biosciences (CTKB) reported revenue of $41.5M for the first quarter 2025 (Q1 2025), -8% from a year earlier and -28% from the quarter before. Operating margin was -36.1%, net loss $11.4M (27.5% of revenue).
Cytek Biosciences, Q1 2025: revenue $41.5M (-8% year over year), operating margin -36.1%, net loss $11.4M, operating cash flow −$125K. The chart follows the revenue to costs, profit and cash.
| Q1 2025 | Amount | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $41.5M | -28% | -8% |
| Operating profit | −$15.0M | — | — |
| Net earnings | −$11.4M | — | — |
| Operating cash flow | −$125K | — | — |
What changed
Revenue was $41.5M in Q1 2025, down 8% year over year and down 28% from the previous quarter. Product was the largest line at 68% of revenue. Product lost $6.0M year over year (down 18%), 177% of the total change.
Gross margin was 48.6%, down 2.7 points from a year earlier. Operating costs exceeded revenue by $15.0M, an operating margin of -36.1%. Operating expenses grew 4% against a revenue fall of 8%. The fastest-growing cost line was General & admin (+13%). The quarter ended with a net loss of $11.4M, after a profit of $9.6M the previous quarter. Non-operating items added $3.7M, -33% of pre-tax earnings, so the bottom line overstates operating performance.
Operating cash flow was −$125K. Non-cash charges added back $1.9M of depreciation and amortization and $6.6M of share-based compensation. Working capital and other items added $2.8M. Capital expenditures of $849K exceeded it, leaving free cash flow of −$1.0M.
Questions
What was Cytek Biosciences' revenue in the first quarter 2025?
Cytek Biosciences (CTKB) reported revenue of $41.5M for the first quarter 2025 (Q1 2025), -8% from a year earlier and -28% from the quarter before.
Was Cytek Biosciences profitable in the first quarter 2025?
Operating loss was $15.0M (-36.1% of revenue) and net loss $11.4M.
Source: Cytek Biosciences 10-Q on SEC EDGAR.